Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuan Yuan
Institutions:
General Hospital of Shenyang Military Region,
Xuzhou Central Hospital,
Liaoning Cancer Hospital & Institute
Observed institutions:
General Hospital of Shenyang Military Region,
Xuzhou Central Hospital,
Liaoning Cancer Hospital & Institute
ORCID:
0000-0002-4241-8902
Observed ORCID:
0000-0002-4241-8902
OpenAlex ID:
A5034436575
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma
2022
·
Zhenggang Ren
, Guoliang Shao
, et al.
·
Liver Cancer
·
16
PDF
The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis
2025
·
Junjie Lin
, Tianshu Ren
, et al.
·
European Journal of Clinical Pharmacology
·
6
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma
2025
·
Zhenggang Ren
, Guoliang Shao
, et al.
·
Cancer Immunology Immunotherapy
·
5
PDF
Show more works
View as search
Works count:
4
Citation count:
32
H-index:
4
I10-index:
1
Year
Topic
Type